Abstract
Finding a means to ameliorate and prevent bone destruction is one of the urgent issues in the treatment of rheumatoid arthritis. Recent studies revealed bone-resorbing osteoclasts to be essential for arthritic bone destruction, but to date there has been scarce experimental evidence for the underlying mechanism of the bone-protective effect of antirheumatic drugs. Here we examined the effects of one or a combination of disease-modifying antirheumatic drugs (DMARDs) on osteoclast differentiation to provide a cellular and molecular basis for their efficacy against bone destruction. The effects on osteoclast precursor cells and osteoclastogenesis-supporting cells were distinguished by two in vitro osteoclast culture systems. Methotrexate (MTX), bucillamine (Buc) and salazosulphapyridine (SASP) inhibited osteoclastogenesis by acting on osteoclast precursor cells and interfering with receptor activator of NF-κB ligand (RANKL)-mediated induction of the nuclear factor of activated T cells (NFAT) c1. MTX and SASP also suppressed RANKL expression on osteoclastogenesis-supporting mesenchymal cells. Interestingly, the combination of three antirheumatic drugs exerted a marked inhibitory effect on osteoclastogenesis even at a low dose at which there was much less of an effect when administered individually. These results are consistent with the reported efficacy of combined DMARDs therapy in humans and suggest that osteoclast culture systems are useful tools to provide an experimental basis for the bone-protective effects of antirheumatic drugs.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
H Takayanagi (2005) ArticleTitleOsteoimmunological insight into bone damage in rheumatoid arthritis Mod Rheumatol 15 225–31 Occurrence Handle17029070 Occurrence Handle10.1007/s10165-005-0398-6
GS Firestein (2003) ArticleTitleEvolving concepts of rheumatoid arthritis Nature 423 356–61 Occurrence Handle12748655 Occurrence Handle10.1038/nature01661 Occurrence Handle1:CAS:528:DC%2BD3sXjs1ynu7c%3D
K Sato H Takayanagi (2006) ArticleTitleOsteoclasts, rheumatoid arthritis, and osteoimmunology Curr Opin Rheumatol 18 419–26 Occurrence Handle16763464 Occurrence Handle10.1097/01.bor.0000231912.24740.a5 Occurrence Handle1:CAS:528:DC%2BD28XlsVeqs7o%3D
H Takayanagi (2005) ArticleTitleInflammatory bone destruction and osteoimmunology J Periodontal Res 40 287–93 Occurrence Handle15966905 Occurrence Handle10.1111/j.1600-0765.2005.00814.x Occurrence Handle1:CAS:528:DC%2BD2MXos1Cgt7g%3D
JS Smolen G Steiner (2003) ArticleTitleTherapeutic strategies for rheumatoid arthritis Nat Rev Drug Discov 2 473–88 Occurrence Handle12776222 Occurrence Handle10.1038/nrd1109 Occurrence Handle1:CAS:528:DC%2BD3sXktFOhu7o%3D
X Le Loet JM Berthelot A Cantagrel B Combe M De Bandt B Fautrel et al. (2006) ArticleTitleClinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology Ann Rheum Dis 65 45–50 Occurrence Handle15994280 Occurrence Handle10.1136/ard.2005.035436 Occurrence Handle1:CAS:528:DC%2BD28Xnt12hug%3D%3D
M Dougados B Combe A Cantagrel P Goupille P Olive M Schattenkirchner et al. (1999) ArticleTitleCombination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components Ann Rheum Dis 58 220–5 Occurrence Handle10364900 Occurrence Handle1:CAS:528:DyaK1MXjtVCru74%3D
L Klareskog D van der Heijde JP de Jager A Gough J Kalden M Malaise et al. (2004) ArticleTitleTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 675–81 Occurrence Handle15001324 Occurrence Handle10.1016/S0140-6736(04)15640-7 Occurrence Handle1:CAS:528:DC%2BD2cXhs12jur4%3D
SL Teitelbaum FP Ross (2003) ArticleTitleGenetic regulation of osteoclast development and function Nat Rev Genet 4 IssueID8 638–49 Occurrence Handle12897775 Occurrence Handle10.1038/nrg1122 Occurrence Handle1:CAS:528:DC%2BD3sXlvFaqtrY%3D
WJ Boyle WS Simonet DL Lacey (2003) ArticleTitleOsteoclast differentiation and activation Nature 423 337–42 Occurrence Handle12748652 Occurrence Handle10.1038/nature01658 Occurrence Handle1:CAS:528:DC%2BD3sXjs1ynu7g%3D
T Suda N Takahashi N Udagawa E Jimi MT Gillespie TJ Martin (1999) ArticleTitleModulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families Endocr Rev 20 345–57 Occurrence Handle10368775 Occurrence Handle10.1210/er.20.3.345 Occurrence Handle1:CAS:528:DyaK1MXktVaqtLg%3D
LE Theill WJ Boyle JM Penninger (2002) ArticleTitleRANK-L and RANK: T cells, bone loss, and mammalian evolution Annu Rev Immunol 20 795–823 Occurrence Handle11861618 Occurrence Handle10.1146/annurev.immunol.20.100301.064753 Occurrence Handle1:CAS:528:DC%2BD38XjtlWgtbo%3D
H Takayanagi (2005) ArticleTitleMechanistic insight into osteoclast differentiation in osteoimmunology J Mol Med 83 170–9 Occurrence Handle15776286 Occurrence Handle10.1007/s00109-004-0612-6 Occurrence Handle1:CAS:528:DC%2BD2MXisVCit7Y%3D
T Koga M Inui K Inoue S Kim A Suematsu E Kobayashi et al. (2004) ArticleTitleCostimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis Nature 428 758–63 Occurrence Handle15085135 Occurrence Handle10.1038/nature02444 Occurrence Handle1:CAS:528:DC%2BD2cXjtV2mt78%3D
FP Ross SL Teitelbaum (2005) ArticleTitleAlphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology Immunol Rev 208 88–105 Occurrence Handle16313343 Occurrence Handle10.1111/j.0105-2896.2005.00331.x Occurrence Handle1:CAS:528:DC%2BD28Xks1eisQ%3D%3D
MC Walsh N Kim Y Kadono J Rho SY Lee J Lorenzo et al. (2006) ArticleTitleOsteoimmunology: interplay between the immune system and bone metabolism Annu Rev Immunol 24 33–63 Occurrence Handle16551243 Occurrence Handle10.1146/annurev.immunol.24.021605.090646 Occurrence Handle1:CAS:528:DC%2BD28XkvFSqt74%3D
H Takayanagi S Kim T Koga H Nishina M Isshiki H Yoshida et al. (2002) ArticleTitleInduction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts Dev Cell 3 889–901 Occurrence Handle12479813 Occurrence Handle10.1016/S1534-5807(02)00369-6 Occurrence Handle1:CAS:528:DC%2BD38XpslClsL8%3D
H Yasuda N Shima N Nakagawa K Yamaguchi M Kinosaki S Mochizuki et al. (1998) ArticleTitleOsteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95 3597–602 Occurrence Handle9520411 Occurrence Handle10.1073/pnas.95.7.3597 Occurrence Handle1:CAS:528:DyaK1cXitlKjsLY%3D
N Takahashi T Akatsu N Udagawa T Sasaki A Yamaguchi JM Moseley et al. (1988) ArticleTitleOsteoblastic cells are involved in osteoclast formation Endocrinology 123 2600–2 Occurrence Handle2844518 Occurrence Handle1:CAS:528:DyaL1cXmt1aquro%3D
M Urushibara H Takayanagi T Koga S Kim M Isobe Y Morishita et al. (2004) ArticleTitleThe antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-κB ligand-stimulated induction of nuclear factor of activated T cells c1 Arthritis Rheum 50 794–804 Occurrence Handle15022321 Occurrence Handle10.1002/art.20206 Occurrence Handle1:CAS:528:DC%2BD2cXjtVCrs7o%3D
EM Gravallese SR Goldring (2000) ArticleTitleCellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis Arthritis Rheum 43 2143–51 Occurrence Handle11037873 Occurrence Handle10.1002/1529-0131(200010)43:10<2143::AID-ANR1>3.0.CO;2-S Occurrence Handle1:CAS:528:DC%2BD3cXnslWjsrs%3D
H Takayanagi H Iizuka T Juji T Nakagawa A Yamamoto T Miyazaki et al. (2000) ArticleTitleInvolvement of receptor activator of nuclear factor kB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis Arthritis Rheum 43 259–69 Occurrence Handle10693864 Occurrence Handle10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W Occurrence Handle1:CAS:528:DC%2BD3cXhs1aqtLw%3D
H Takayanagi H Oda S Yamamoto H Kawaguchi S Tanaka T Nishikawa et al. (1997) ArticleTitleA new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis Biochem Biophys Res Commun 240 279–86 Occurrence Handle9388467 Occurrence Handle10.1006/bbrc.1997.7404 Occurrence Handle1:CAS:528:DyaK2sXnsFWnt7g%3D
AR Pettit H Ji D von Stechow R Muller SR Goldring Y Choi et al. (2001) ArticleTitleTRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis Am J Pathol 159 1689–99 Occurrence Handle11696430 Occurrence Handle1:STN:280:DC%2BD3Mnltl2rsA%3D%3D
K Redlich S Hayer R Ricci JP David M Tohidast-Akrad G Kollias et al. (2002) ArticleTitleOsteoclasts are essential for TNF-α-mediated joint destruction J Clin Invest 110 1419–27 Occurrence Handle12438440 Occurrence Handle10.1172/JCI200215582 Occurrence Handle1:CAS:528:DC%2BD38XovFOnu7s%3D
H Takayanagi T Juji T Miyazaki H Iizuka T Takahashi M Isshiki et al. (1999) ArticleTitleSuppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts J Clin Invest 104 137–46 Occurrence Handle10411542 Occurrence Handle1:CAS:528:DyaK1MXkslSmsb4%3D
YY Kong U Feige I Sarosi B Bolon A Tafuri S Morony et al. (1999) ArticleTitleActivated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 402 304–9 Occurrence Handle10580503 Occurrence Handle10.1038/46303 Occurrence Handle1:CAS:528:DyaK1MXnvFShsLg%3D
E Lubberts LA Joosten M Chabaud L van Den Bersselaar B Oppers CJ Coenen-De Roo et al. (2000) ArticleTitleIL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion J Clin Invest 105 1697–710 Occurrence Handle10862785 Occurrence Handle1:CAS:528:DC%2BD3cXkt1Wqs7g%3D
P Ranganathan HL McLeod (2006) ArticleTitleMethotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis Arthritis Rheum 54 1366–77 Occurrence Handle16645965 Occurrence Handle10.1002/art.21762 Occurrence Handle1:CAS:528:DC%2BD28XlsFSqurw%3D
N Sekiguchi H Kameda K Amano T Takeuchi (2006) ArticleTitleEfficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis Mod Rheumatol 16 85–91 Occurrence Handle16633927 Occurrence Handle10.1007/s10165-005-0466-y Occurrence Handle1:CAS:528:DC%2BD28XjslKit70%3D
M Nagashima G Shu K Yamamoto S Yamahatsu S Yoshino (2005) ArticleTitleThe ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis. epidemiology of DMARDs treatment in Japan Clin Exp Rheumatol 23 27–35 Occurrence Handle15789884 Occurrence Handle1:STN:280:DC%2BD2M7lslWmtA%3D%3D
Tsuji F, Aono H, Okamoto M, Sasano M. Bucillamine, A unique anti-rheumatic drug. Curr Top Pharmacol [in press]
H Takayanagi K Ogasawara S Hida T Chiba S Murata K Sato et al. (2000) ArticleTitleT-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ Nature 408 600–5 Occurrence Handle11117749 Occurrence Handle10.1038/35046102 Occurrence Handle1:CAS:528:DC%2BD3cXovFajs7c%3D
T Koga Y Matsui M Asagiri T Kodama B de Crombrugghe K Nakashima et al. (2005) ArticleTitleNFAT and Osterix cooperatively regulate bone formation Nat Med 11 880–5 Occurrence Handle16041384 Occurrence Handle10.1038/nm1270 Occurrence Handle1:CAS:528:DC%2BD2MXmvFemsL0%3D
CK Lee EY Lee SM Chung SH Mun B Yoo HB Moon (2004) ArticleTitleEffects of disease-modifying antirheumatic drugs and anti-inflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand Arthritis Rheum 50 3831–43 Occurrence Handle15593184 Occurrence Handle10.1002/art.20637 Occurrence Handle1:CAS:528:DC%2BD2MXls1ehuw%3D%3D
M Asagiri K Sato T Usami S Ochi H Nishina H Yoshida et al. (2005) ArticleTitleAutoamplification of NFATc1 expression determines its essential role in bone homeostasis J Exp Med 202 1261–9 Occurrence Handle16275763 Occurrence Handle10.1084/jem.20051150 Occurrence Handle1:CAS:528:DC%2BD2MXht1Sntr%2FE
K Sato A Suematsu K Okamoto A Yamaguchi Y Morishita Y Kadono et al. (2006) ArticleTitleTh17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction J Exp Med 203 2673–82 Occurrence Handle17088434 Occurrence Handle10.1084/jem.20061775 Occurrence Handle1:CAS:528:DC%2BD28Xht12htLfJ
M Bromley DE Woolley (1984) ArticleTitleChondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint Arthritis Rheum 27 968–75 Occurrence Handle6236824 Occurrence Handle1:STN:280:BiuA3cjovFQ%3D
G Schett S Hayer J Zwerina K Redlich JS Smolen (2005) ArticleTitleMechanisms of disease: the link between RANKL and arthritic bone disease Nat Clin Pract Rheumatol 1 47–54 Occurrence Handle16932627 Occurrence Handle10.1038/ncprheum0036 Occurrence Handle1:CAS:528:DC%2BD28Xis1arur8%3D
C Dong (2006) ArticleTitleDiversification of T-helper-cell lineages: finding the family root of IL-17-producing cells Nat Rev Immunol 6 329–33 Occurrence Handle16557264 Occurrence Handle10.1038/nri1807 Occurrence Handle1:CAS:528:DC%2BD28XivVyqsr4%3D
Y Munakata S Iwata J Dobers T Ishii M Nori H Tanaka et al. (2000) ArticleTitleNovel in vitro effects of bucillamine: inhibitory effects on proinflammatory cytokine production and transendothelial migration of T cells Arthritis Rheum 43 1616–23 Occurrence Handle10902767 Occurrence Handle10.1002/1529-0131(200007)43:7<1616::AID-ANR27>3.0.CO;2-I Occurrence Handle1:CAS:528:DC%2BD3cXlsV2mtrg%3D
H Aono T Hasunuma K Fujisawa T Nakajima K Yamamoto S Mita et al. (1996) ArticleTitleDirect suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine J Rheumatol 23 65–70 Occurrence Handle8838510 Occurrence Handle1:CAS:528:DyaK28Xht1ahsrc%3D
S Liptay M Bachem G Hacker G Adler KM Debatin RM Schmid (1999) ArticleTitleInhibition of nuclear factor κB and induction of apoptosis in T-lymphocytes by sulfasalazine Br J Pharmacol 128 1361–9 Occurrence Handle10602313 Occurrence Handle10.1038/sj.bjp.0702937 Occurrence Handle1:CAS:528:DyaK1MXotFSisLg%3D
FC Breedveld P Emery E Keystone K Patel DE Furst JR Kalden et al. (2004) ArticleTitleInfliximab in active early rheumatoid arthritis Ann Rheum Dis 63 149–55 Occurrence Handle14722203 Occurrence Handle10.1136/ard.2003.013961 Occurrence Handle1:CAS:528:DC%2BD2cXhsVGnsLY%3D
Y Ichikawa T Saito H Yamanaka M Akizuki H Kondo S Kobayashi et al. (2005) ArticleTitleTherapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study Mod Rheumatol 15 323–8 Occurrence Handle17029087 Occurrence Handle10.1007/s10165-005-0420-z Occurrence Handle1:CAS:528:DC%2BD2MXhtFWmtLbF
EH Choy GS Panayi (2001) ArticleTitleCytokine pathways and joint inflammation in rheumatoid arthritis N Engl J Med 344 907–16 Occurrence Handle11259725 Occurrence Handle10.1056/NEJM200103223441207 Occurrence Handle1:CAS:528:DC%2BD3MXisFyrur8%3D
M Feldmann RN Maini (2001) ArticleTitleAnti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19 163–96 Occurrence Handle11244034 Occurrence Handle10.1146/annurev.immunol.19.1.163 Occurrence Handle1:CAS:528:DC%2BD3MXivFKgtbg%3D
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Suematsu, A., Tajiri, Y., Nakashima, T. et al. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol 17, 17–23 (2007). https://doi.org/10.1007/s10165-006-0531-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-006-0531-1